Key Takeaways

Ibutamoren is often grouped with peptides, but it is an oral small molecule that stimulates the ghrelin receptor and can raise endogenous GH and IGF-1. It has real human research and an active pediatric Phase 3 program.
The clinically honest summary is narrower than the market story: biomarker effects are better established than broad patient outcomes, pediatric GHD development does not validate adult wellness use, and FDA currently flags both compounding and safety concerns.

‍

[FDA, 2024; FDA, 2026; ClinicalTrials.gov, 2026]

‍

Ibutamoren mesylate / MK-677: an unapproved, investigational, orally active nonpeptide ghrelin-receptor agonist and growth-hormone secretagogue; the mesylate salt of ibutamoren, now developed as LUM-201 in selected children with growth hormone deficiency.

Overview

Ibutamoren mesylate has a more substantial same-molecule human evidence base than many compounds circulating in the peptide market, but that makes the evidence-transfer problem easier to miss, not less important. Ibutamoren is not a peptide. It is an orally active small molecule that agonizes the ghrelin/growth-hormone secretagogue receptor and can increase growth hormone and insulin-like growth factor 1 in defined study settings. Those pharmacodynamic effects are real. They do not, by themselves, establish that consumer MK-677 builds functional muscle, reduces body fat, accelerates injury recovery, improves sleep disorders, prevents fractures, or slows aging in healthy adults. [Patchett et al., 1995; Pong et al., 1996; Chapman et al., 1996; Nass et al., 2008]

The strongest current development path is LUM-201 in pediatric growth hormone deficiency, where a sponsor is using a predictive enrichment strategy to select children with residual hypothalamic-pituitary function who may respond to oral secretagogue therapy. A 12-month multinational Phase 3 trial is recruiting, and a long-term safety-extension study is registered. That program is population-, formulation-, and selection-specific. It cannot be rewritten as proof for adult anti-aging, bodybuilding, fat-loss, recovery, or general wellness use, and a Phase 3 program is not FDA approval. [ClinicalTrials.gov, 2026; Lumos Pharma, 2026; Bright et al., 2021; Bright and Thorner, 2022]

The regulatory posture is actively cautionary. FDA currently lists ibutamoren mesylate in Category 2 under both the 503A and 503B interim compounding policies, identifying a potential congestive-heart-failure risk. At the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, the committee voted 13 to 1, with no abstentions, against placing ibutamoren mesylate on the 503A Bulks List; members cited insufficient efficacy and safety support, fluid retention, congestive heart failure, and hyperglycemia. [FDA, 2024; FDA, 2026; Federal Register, 2024]

The market legitimacy frame is unusually persuasive because the compound is oral, can raise the body's own GH and IGF-1 rather than supplying recombinant GH, has decades of human research, and is in late-stage pediatric development. The omitted facts are that biomarker elevation is not the same as clinical benefit; adult trials produced mixed or negative outcome results; fluid-retention and glucose effects are recurrent safety themes; a hip-fracture trial was terminated early over a possible heart-failure signal; the substance is prohibited in sport; and recent FDA and TGA actions document hidden-ingredient and adulteration risks in consumer products. [Adunsky et al., 2011; FDA, 2025; FDA, 2026; WADA, 2026; TGA, 2026]

What it is

Ibutamoren is a synthetic, orally active, nonpeptide small molecule originally developed under codes including L-163,191, MK-0677, and MK-677. PubChem lists the free-base molecular formula as C27H36N4O5S and a molecular weight of approximately 528.7 g/mol. A separate PubChem record for the mesylate form lists C28H40N4O8S2 and approximately 624.8 g/mol. Because the target compound is not an amino-acid chain, there is no canonical peptide sequence to report. [Patchett et al., 1995; PubChem, 2026]

The "mesylate" label is not cosmetic. It identifies a salt form formed with methanesulfonic acid, while "ibutamoren" can refer to the free base or to the active moiety more generally. FDA's 2024 review focused on ibutamoren mesylate as the nominated bulk drug substance and noted that the publicly submitted certificates of analysis did not include adequate information on chiral purity, drug-substance-related impurities, or residual solvents. [FDA, 2024]

LUM-201 is the current development name for an oral ibutamoren program in pediatric GHD. It is not a different pharmacologic class, but it is a specific sponsor-controlled clinical product, study protocol, manufacturing system, and patient-selection strategy. Evidence from LUM-201 trials may inform ibutamoren biology, but it does not validate unknown online capsules, a compounded preparation, or consumer "MK-677" products with different sourcing and quality controls. [ClinicalTrials.gov, 2026; Lumos Pharma, 2026]

A second identity problem is category confusion. Ibutamoren is often placed beside CJC-1295, ipamorelin, sermorelin, and tesamorelin because all can be discussed through the GH axis. Chemistry and receptor pharmacology differ. Ibutamoren is a nonpeptide ghrelin-receptor agonist; GHRH analogs act through the GHRH receptor; recombinant somatropin supplies exogenous GH; and peptide secretagogues such as ipamorelin are amino-acid compounds. Ibutamoren is also not a selective androgen receptor modulator, even though it is frequently marketed in SARM-adjacent bodybuilding channels. [Pong et al., 1996; FDA, 2024; OPSS, 2024]

Material	What it is	Why it cannot be collapsed into "ibutamoren mesylate / MK-677"
Endogenous ghrelin	A naturally occurring peptide hormone and endogenous ligand for the ghrelin receptor.	Ibutamoren mimics selected receptor signaling but does not reproduce the full regulated physiology, distribution, or timing of endogenous ghrelin.
Ibutamoren mesylate	The mesylate salt reviewed by FDA for 503A/503B compounding and used in much of the historical literature.	This is the target regulatory substance. Product quality and formulation still vary across clinical, compounded, and gray-market sources.
LUM-201	Sponsor-controlled oral ibutamoren product in pediatric GHD development.	Late-stage development in selected children does not validate adult wellness, bodybuilding, sleep, or anti-aging use.
Recombinant human GH / somatropin	Exogenous growth hormone supplied directly as a drug.	Different molecule, route, PK, label, monitoring, and evidence base.
SARM-labeled or multi-ingredient products	Bodybuilding products that may group MK-677 with SARMs or contain undeclared ingredients.	Ibutamoren is not a SARM, and a stack or mislabeled product is not the same intervention studied in controlled trials.

How it's proposed to work

The most defensible mechanistic anchor is agonism of the growth hormone secretagogue receptor type 1a, now commonly called the ghrelin receptor. The original medicinal-chemistry program described L-163,191/MK-0677 as a potent, orally active growth-hormone secretagogue, and subsequent receptor work identified the G-protein-linked receptor through which synthetic secretagogues act. The receptor is distinct from the growth hormone-releasing hormone receptor. [Patchett et al., 1995; Pong et al., 1996; FDA, 2024]

At the hypothalamic-pituitary level, receptor activation can increase endogenous GH secretion, with downstream increases in IGF-1 and IGF-binding protein 3 in some human studies. In healthy older adults, selected adults with GH deficiency, and some children with GHD, short-term oral administration increased GH-axis biomarkers. That supports the phrase "stimulates endogenous GH secretion" within the conditions of the cited studies. It does not support "oral HGH," because the compound is not GH and does not supply recombinant hormone. [Chapman et al., 1996; Chapman et al., 1997; Codner et al., 2001]

Response depends on residual axis function. A secretagogue requires a responsive hypothalamic-pituitary system and does not create the same exposure pattern as direct somatropin administration. The modern LUM-201 program therefore uses a predictive enrichment marker strategy that combines baseline IGF-1 and acute GH response testing to identify children more likely to respond. [Bright et al., 2021; Bright and Thorner, 2022; Lumos Pharma, 2026]

Ghrelin-receptor signaling also helps explain appetite and sleep-related observations. Appetite increase appears repeatedly in human and regulatory sources, and small controlled sleep studies reported changes in sleep architecture or quality. [Copinschi et al., 1997; Nass et al., 2008]

The mechanism map also explains the safety tensions. Raising GH/IGF-1 and activating ghrelin pathways can be accompanied by edema or water retention, musculoskeletal symptoms, increased appetite, and changes in fasting glucose or insulin sensitivity. In an older post-hip-fracture population, a Phase IIb study was terminated early after a potential congestive-heart-failure signal. [Nass et al., 2008; Adunsky et al., 2011; FDA, 2024]

Common forms in circulation

FDA's 2024 PCAC review described the nominated compounded dosage forms as oral capsules or tablets, with nominated 10-mg and 25-mg strengths. FDA also noted that none of the reviewed clinical studies appeared to use a compounded formulation. [FDA, 2024]

In the current sponsor-controlled development program, LUM-201 is administered orally as a capsule containing minitablets and is compared with matching placebo in treatment-naive prepubertal children selected for pediatric GHD. [ClinicalTrials.gov, 2026; Lumos Pharma, 2026]

Consumer pages describe oral capsules or tablets, often contrasting MK-677 with injectable GH-axis peptides. Recent enforcement and international alerts show why product form cannot be taken at face value: FDA laboratory testing found undeclared ibutamoren mesylate in products promoted for children's growth, while Australia's TGA found an MK-677 product labeled as ibutamoren that also contained undeclared metandienone, an anabolic steroid. [FDA, 2025; TGA, 2026]

Names and aliases

Scientific and development names include ibutamoren, ibutamoren mesylate, MK-677, MK 677, MK677, MK 0677, MK0677, L-163,191, and LUM-201. Category labels to correct: "peptide," "oral HGH," "GH peptide," and "SARM" — ibutamoren is a nonpeptide ghrelin-receptor agonist and is not a SARM. [FDA, 2024; FDA, 2026; NCATS Inxight Drugs, 2026; OPSS, 2024]

Regulatory status

Ibutamoren mesylate has no FDA-approved indication. FDA identifies ibutamoren as an active ingredient that is not approved and has determined that it is excluded from the dietary-supplement definition because it was authorized for investigation as a new drug before evidence of prior food or supplement marketing. FDA's 2025 Agebox warning letter therefore treated ibutamoren-containing products promoted as supplements as unapproved new drugs and misbranded drugs. [FDA, 2025; FDA, 2026]

The current compounding posture is precise and unfavorable. FDA's May 14, 2026 503A nomination document lists ibutamoren mesylate in Category 2, the category for bulk drug substances that raise significant safety risks. FDA's current safety-risk page lists it in Category 2 under both 503A and 503B. FDA's stated rationale is the potential for congestive heart failure in certain patients, including the early termination of a randomized hip-fracture trial over a possible heart-failure signal. [FDA, 2025; FDA, 2026]

The active LUM-201 program does not change that status. A 12-month randomized, double-blind, placebo-controlled Phase 3 study is recruiting selected, treatment-naive prepubertal children with GHD, and a long-term safety-extension study is registered. These are investigational studies and do not establish approval, commercial labeling, or adult use. [ClinicalTrials.gov, 2026; Lumos Pharma, 2026]

FDA evaluated ibutamoren mesylate for growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity, and Alzheimer's disease at the October 29, 2024 PCAC meeting. The committee voted 1 yes, 13 no, and 0 abstentions. The majority concluded that the evidence presented did not support clinical efficacy and safety and expressed concern about fluid retention, congestive heart failure, and hyperglycemia. FDA's chemistry review also concluded that ibutamoren mesylate was not well characterized because critical data on chiral purity, drug-substance-related impurities, and residual solvents were not available. [Federal Register, 2024; FDA, 2024]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Prospective human intervention with the same active moiety, defined salt/formulation and route where relevant, a named population, comparator, duration, and patient-centered or validated surrogate outcome.	Transfer from selected pediatric GHD to healthy adults; from GH/IGF-1 biomarkers to muscle, recovery, sleep, or longevity; or from a sponsor formulation to unknown consumer products.
Animal model	In vivo ibutamoren or ghrelin-receptor-agonist work in a specified species and disease or physiology model.	Human efficacy, human dosing, human long-term safety, or route equivalence.
Mechanistic hypothesis	Receptor binding, pituitary or hypothalamic signaling, GH pulse analysis, IGF-1/IGFBP-3 changes, appetite signaling, or cell/tissue studies.	"Builds muscle," "burns fat," "heals," "improves sleep," or "slows aging" as generalized patient outcomes.
Anecdotal or commercial	Clinic pages, bodybuilding forums, testimonials, research-chemical pages, stack logic, product listings, or user-reported sleep/recovery effects.	Any evidence-backed efficacy, safety, product-quality, or validated-dose claim.

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it does not support
Pediatric GHD / linear growth	Short-term pediatric studies reported GH, IGF-1, and IGFBP-3 responses in some children, and current LUM-201 trials use a predictive enrichment strategy to identify likely responders. A multinational 12-month Phase 3 trial is active and enrolling.	"Approved oral growth-hormone treatment," guaranteed height gain, use in children without diagnosed GHD, or transfer to hidden-ingredient supplements. [Codner et al., 2001; Bright et al., 2021; ClinicalTrials.gov, 2026]
Raises GH and IGF-1	Multiple human studies in older adults, selected GH-deficient adults, and children reported increases in GH-axis biomarkers after oral MK-677/ibutamoren.	"Normalizes hormones," "replaces HGH," or any automatic claim of symptom, performance, or disease improvement. [Chapman et al., 1996; Chapman et al., 1997; Codner et al., 2001]
Lean mass / sarcopenia support	In a randomized trial of healthy older adults, MK-677 increased fat-free mass relative to placebo. The same trial did not show corresponding improvement in strength or physical function.	"Builds functional muscle," "treats sarcopenia," "bodybuilding drug," or guaranteed strength gain. [Nass et al., 2008]
Fat loss / body recomposition	An 8-week trial in obese men reported higher GH, IGF-1, fat-free mass, and energy expenditure, but no significant reduction in total or visceral fat.	"Fat burner," "visceral-fat reducer," "recomp peptide," or weight-loss treatment claims. [Svensson et al., 1998; Nass et al., 2008]
Bone turnover / osteoporosis	Trials reported increased bone-turnover markers, and a postmenopausal osteoporosis study found an additional femoral-neck BMD signal when MK-677 was combined with alendronate.	"Treats osteoporosis," "prevents fractures," or "restores bone density." Bone turnover acceleration is not itself a clinical benefit. [Murphy et al., 1999; Murphy et al., 2001]
Hip-fracture recovery	A hip-fracture trial reported no clear improvement in major functional outcomes, and a later Phase IIb trial was terminated early after a potential CHF safety signal.	"Accelerates fracture recovery," "restores mobility," or post-surgical recovery marketing. [Bach et al., 2004; Adunsky et al., 2011]
Sleep quality / deep sleep	Small studies reported changes in sleep architecture or sleep-quality measures during short-term MK-677 exposure.	Treatment of insomnia, sleep apnea, chronic sleep disturbance, recovery enhancement, or a general "deep sleep drug" claim. [Copinschi et al., 1997]
Alzheimer's disease / cognition	A 12-month randomized trial in 563 patients showed substantial IGF-1 elevation but no clinical effect on Alzheimer's disease progression.	Cognitive enhancement, neuroprotection, dementia treatment, or using IGF-1 elevation as a proxy for brain benefit. [Sevigny et al., 2008]

Key literature

Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the GH-IGF-I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. Shows oral MK-677 can increase GH secretion and IGF-1 in healthy older adults.

Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. Best direct evidence for increased fat-free mass and GH/IGF-1 in healthy older adults; documents appetite, edema, muscle pain, and glucose-related effects, without corresponding strength or functional improvement.

Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708. Substantial IGF-1 elevation did not slow Alzheimer progression in a 563-patient trial.

Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-189. Early termination after a potential CHF signal and limited functional benefit.

Bright GM, Do MT, McKew JC, Blum WF, Thorner MO. Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency. J Endocr Soc. 2021;5(6):bvab030. Rationale for selecting likely pediatric responders based on residual GH-axis function.

References

U.S. Food and Drug Administration. FDA Briefing Document: Evaluation of Ibutamoren Mesylate for Inclusion on the 503A Bulk Drug Substances List. October 29, 2024.
U.S. Food and Drug Administration. Agebox iKids Growth Day Formula May Be Harmful Due to Hidden Ingredient. Content current September 23, 2025.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed July 16, 2026.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. 89 FR 76478. September 18, 2024.
PubChem. Ibutamoren. CID 178024.
ClinicalTrials.gov. A Multicenter, 12-Month, Randomized, Double-Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency. NCT06948214.
World Anti-Doping Agency. The 2026 Prohibited List. Effective January 1, 2026.
Therapeutic Goods Administration. Unapproved Ibutamoren Capsules (MK-677) Found to Contain Undisclosed Anabolic Steroid. June 4, 2026.
Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611.
Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.
Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture. Arch Gerontol Geriatr. 2011;53(2):183-189.

Ibutamoren Mesylate (MK-677)